Cerapedics received the CE Mark in Europe and Therapeutic Goods Administration listing in Australia for its new i-FACTOR Flex FR biologic bone graft.
The graft features the company's proprietary synthetic small peptide bone graft technology as well as purified silk fibers to provide enhanced cohesion, mechanical properties and handling characteristics. The graft has been used primarily in spinal fusion applications, and Cerapedics, thus far, has conducted a limited market release for the bone graft.
"We are pleased to receive CE Mark approval and TGA listing for the new i-FACTOR Flex FR biologic bone graft," said Glen Kashuba, CEO of Cerapedics. "Silk has been used in medical applications for many years, and by adding purified silk fibers to the proven efficacy and safety of our P-15 bone graft technology we are now able to pursue exciting new applications for this platform."
More articles on devices:
Could Congress repeal the medical device tax without Obama? 5 things to know
K2M revenue up 18% in 2014 — 5 things to know
Stryker's 4Q, 2014 sales up, but stock performance disappoints — 8 key notes